ReviewJournal of clinical hypertension (Greenwich, Conn.)2008
Blood pressure control in patients with comorbidities.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).Journal of human hypertension · 2013Trial
- Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.Cardiovascular diabetology · 2012Trial
- Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome.Journal of human hypertension · 2011Trial
- Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups.Journal of the American Society of Hypertension : JASHTrial
- The Desert Duo: A Narrative Review on How Camel Milk and Date Fruits Combat Oxidative Stress and Enhance Metabolic Health.Antioxidants (Basel, Switzerland) · 2026Review
- Hypertensive Heart Failure with Preserved Ejection Fraction: Guidelines vs. Randomized Controlled Trials Evidence Gaps.Medicina (Kaunas, Lithuania) · 2026Review
- Predictors of time to blood pressure control among hypertensive patients in pastoral communities of the Afar region, Northeastern Ethiopia.Global epidemiology · 2026Article
- Analysis of Infection Types, Pathogens, Antimicrobial Treatment, and Clinical Outcomes Data in Hospitalised Patients: Comprehensive Online Database for Antimicrobial Resistance (CODAR) Retrospective Pilot Study.Journal of epidemiology and global health · 2026Article
- Fruit and Vegetable Consumption and Its Public Health Implications for Hypertension Among Peruvian Aged 15 Years and Older: Evidence from the 2022-2023 Demographic and Health Survey.Healthcare (Basel, Switzerland) · 2026Article
- Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists.Current hypertension reports · 2025Review
- Comprehensive Cardiovascular Risk Factor Control With a Mobile Health Cardiovascular Risk Self-Management Program.Journal of the American Heart Association · 2024Article
- Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features.Pharmaceutics · 2024Review
- Prevalence and Risk Factors of Hypertension in Hargeisa, Somaliland: A Hospital-Based Cross-Sectional Study.Diseases (Basel, Switzerland) · 2023Article
- Hypertension Control Cascade and Regional Performance in India: A Repeated Cross-Sectional Analysis (2015-2021).Cureus · 2023Article
- Predictors of non-adherence to antihypertensive medications: A cross-sectional study from a regional hospital in Afghanistan.PloS one · 2023Article
- Atherogenic dyslipidemia and associated risk factors among hypertensive patients of five health facilities in Northeast Ethiopia.PloS one · 2023Article
- Antihypertensive and Statin Medication Adherence Among Medicare Beneficiaries.American journal of preventive medicine · 2022Article
- Uncontrolled blood pressure and contributing factors among patients with hypertension at outpatient care of Bedele General Hospital, Southwest Ethiopia: A cross-sectional study.SAGE open medicine · 2022Article
- Controlled Blood Pressure in Iranian Patients: A Multi-Center Report.Global journal of health science · 2015Article
- Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial.International journal of hypertension · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension frequently coexists with obesity, diabetes, hyperlipidemia, or the metabolic syndrome; their association with cardiovascular disease is well established. The identification and management of these risk factors is an important part of the overall management of hypertensive patients. Because patients in these special populations are more predisposed to target organ damage (TOD), stringent targets for blood pressure (BP) control have been set in clinical guidelines. However, clinical trial and real-life evidence suggest that these targets are difficult to achieve. Patients with these comorbidities are more likely to require combination therapy, yet physicians are often reluctant to adjust the number and doses of medications to achieve target BP. There is a particular need for effective 24-hour BP control in these patients, due to the increased likelihood of nondipping status, which is a risk factor for TOD and mortality. Not all available antihypertensives are equally effective in controlling BP over 24 hours, and some may exacerbate underlying metabolic abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.